Potential conflict of interest: L.K. and R.S. are advisors to Nordion and Bayer/Onyx. L.K. is on the speakers- bureau and received grants from Bayer/Onyx. M.M. received grants from Nordion. R.S. consults for and received grants from Nordion and consults for Bayer/Onyx.
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib
Version of Record online: 1 OCT 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 5, pages 1655–1666, November 2013
How to Cite
Vouche, M., Kulik, L., Atassi, R., Memon, K., Hickey, R., Ganger, D., Miller, F. H., Yaghmai, V., Abecassis, M., Baker, T., Mulcahy, M., Nayar, R., Lewandowski, R. J. and Salem, R. (2013), Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology, 58: 1655–1666. doi: 10.1002/hep.26487
- Issue online: 30 OCT 2013
- Version of Record online: 1 OCT 2013
- Accepted manuscript online: 22 MAY 2013 10:46AM EST
- Manuscript Accepted: 21 APR 2013
- Manuscript Received: 21 FEB 2013
- National Instututes of Health. Grant Number: CA126809
Additional Supporting Information may be found in the online version of this article.
|hep26487-sup-0001-supptables.doc||252K||Supplementary Table 1: MRI protocol|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.